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CORRESPONDENCE
Re: Germline BRCA1
Mutations and a Basal
Epithelial Phenotype in Breast
Cancer
Foulkes et al. (1) reported that the
expression of cytokeratin 5/6, indicating
a basal epithelial phenotype, was statisti-
cally significantly associated with germ-
line BRCA1 mutations in estrogen re-
ceptor (ER)- and erbB2-negative invasive
breast cancers. It has recently been
shown that the epidermal growth factor
receptor (EGFR) is often expressed in
basal-type (“stem”) cells of the breast
(2), extending the phenotype of basal
cells to ER–/erbB2–/EGFR breast cells.
We examined the expression of EGFR
by immunohistochemistry in the inva-
sive breast cancers from 21 proven car-
riers of BRCA1 germline mutations
and five proven carriers of BRCA2
germline mutations, as well as from a
control group of 430 invasive breast
cancers from patients unselected for a
family history of breast cancer. Only
clear membrane staining for EGFR was
considered as overexpression. Of the 21
BRCA1-related breast cancers, 14 (67%)
showed EGFR overexpression, 19
(90%) were ER negative, and 17 (81%)
were erbB2 negative. Eleven (52%) of
21 tumors were ER–/erbB2–/EGFR.
All five (100%) breast cancers in
BRCA2 mutation carriers showed
EGFR overexpression, four (80%)
were ER negative, and three (75%) of
four were erbB2 negative (one could
not be characterized). Two (50%) of
four tumors were ER–/erbB2–/EGFR.
In the control group of 430 tumors,
EGFR overexpression was found in
only 70 (16%), and only 28 (7%) of
422 tumors were ER–/erbB2–/EGFR.
(Eight tumors could not be character-
ized for both proteins.) EGFR overex-
pression was statistically significantly
higher in breast cancers in BRCA1
(P.001, two-sided Fisher’s exact
test) and BRCA2 (P.001) mutation
carriers than in the control tumors.
Also, the full ER–/erbB2–/EGFR
phenotype was statistically signifi-
cantly more frequent in BRCA1/2 mu-
tation carriers (P.001).
The high frequency of EGFR overex-
pression fits with the poor prognosis for
patients with hereditary breast cancer,
but the underlying mechanism is yet un-
clear. Amplification of EGFR seems to
be very rare in invasive breast cancer
(Buerger H, unpublished data). Further,
by comparative genomic hybridization,
amplification at the EGFR locus was not
observed (3). Genetic alterations in an
expression-regulating CA repeat in the
first intron of the EGFR gene (4) have
not yet been studied in hereditary breast
cancer. In two gene expression studies
in hereditary breast cancer (5,6), in-
creased EGFR mRNA expression was
not observed, indicating that EGFR ex-
pression is probably largely posttran-
scriptionally regulated.
We conclude that invasive breast car-
cinomas in patients with a BRCA1 or
BRCA2 germline mutation show a high
frequency of EGFR overexpression,
compatible with the previously (7) es-
tablished predominantly basal pheno-
type (ER–/erbB2–) of these cancers and
their aggressive clinical behavior. Thus,
we urge further investigation into the
mechanisms of EGFR overexpression
and into new preventive strategies
through EGFR targeting.
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Several reports have established
that sporadic breast carcinomas with
expression of basal cell (myoepithelial
cell) markers, such as P-cadherin and
high molecular weight cytokeratins
CK5/6, CK14, and CK17, show spe-
cific morphologic and prognostic char-
acteristics (1,2). In cDNA studies, Perou
et al. (3) also defined a subgroup of
estrogen receptor (ER)-negative/HER2-
negative breast cancers characterized by
the expression of the basal cell markers.
Recently, Sorlie et al. (4) reanalyzed
cDNA microarray data from van’t Veer
et al. (5) and observed that most carci-
nomas with a BRCA1 mutation had the
gene expression profile of basal type
cells. In a recent issue of this Journal,
Foulkes et al. (6) reported that the ex-
pression of CK5/6 was statistically sig-
nificantly associated with ER-negative/
HER2-negative BRCA1-related cancers
(15 [88%] of 17 tumors), when com-
pared with ER-negative/HER2-negative
sporadic cancers (25 [45%] of 55 tu-
mors) in Askenazi Jewish women younger
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than 65 years. In addition, we have re-
cently reported that the expression of
P-cadherin is also most common in
BRCA1-related cancers than in familial
BRCA2-related and non-BRCA1/2- re-
lated cancers (7).
To further test the hypothesis that the
basal cell phenotype is BRCA1-related,
we analyzed the basal cytokeratin
CK5/6 and the ductal cytokeratin CK8
in infiltrating ductal carcinomas (IDCs)
from 20 patients with a BRCA1 muta-
tion (mean age  42 years) and 14 pa-
tients with a BRCA2 mutation (mean
age  42.6 years) genes. The morpho-
logical and some immunohistochemical
features of this series have been recently
published (7). In addition, 59 patients
with non-familial IDCs (mean age 
42.6 years) were studied, as an age-
matched control group. All tumors were
included in a tissue microarray and sub-
jected to immunohistochemistry as pre-
viously described (7). Positive CK5/6
expression was as reported by Foulkes
et al. (6). Reduced expression of CK8
was recorded when less than 50% of
tumor cells expressed this marker.
In our series, CK5/6 was expressed in
nine (45%) of 20 BRCA1-related carci-
nomas, one (7%) of 14 BRCA2-related
carcinomas, and five (8%) of 59 spo-
radic breast carcinomas, respectively
(P.001) (Fig. 1). The ER-negative/
HER2-negative phenotype was present
in 15 (75%), one (7%), and eight (14%)
of the BRCA1-related, BRCA2-related,
and sporadic breast cancers, respec-
tively (P.001). The complete ER-
negative/HER2-negative and CK5/6-
positive phenotype was observed in
nine (45%), one (7%), and three (5%)
BRCA1-related, BRCA2-related, and
sporadic breast carcinomas, respec-
tively (P.001). When we considered
only cases with an ER-negative/
HER2-negative phenotype, CK5/6 was
expressed in nine (60%) of 15 BRCA1-
related carcinomas and three (37%) of
eight sporadic breast carcinomas, although
this difference was not statistically signif-
icant, in contrast to the results of Foulkes
et al. (6). The smaller number of case
patients and the different ethnic popula-
tion analyzed in our study may explain the
discrepancies between series. In this
sense, most case patients in the study of
Foulkes et al. (6) were probably related to
the BRCA1 Ashkenazi Jewish founder
mutations, which could be associated with
a more homogeneous breast cancer phe-
notype. In any case, the present study sup-
ports the existence of a subtype of high-
grade, ER-negative/HER2-negative breast
carcinomas with a basal phenotype that
occurs more frequently in BRCA1-related
than in sporadic carcinomas. This pheno-
type can also occur, although very infre-
quently, in BRCA2-related breast cancer.
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Fig. 1. A) Differential expression profiles between BRCA1 (column 1) and
BRCA2 (column 2) tumors. Using the immunohistochemical expression of
the markers shown on the right, the majority of the BRCA1 tumors (red
bar) and the majority of the BRCA2 tumors (blue bar) were grouped in
distinct clusters. Only the BRCA2-related carcinoma expressing cytokera-
tin (CK) 5/6 is grouped with BRCA1-related carcinomas. B) Cluster
analysis of BRCA1 tumors (column 1) and sporadic breast carcinomas
(column c) defines two main branches, one composed of estrogen receptor
(ER)-positive carcinomas and the other one of ER-negative carcinomas.
In this later branch, sub-branches containing HER2-positive (blue bar)
and CK5/6-positive tumors (red bar) are clearly distinguished. Statisti-
cal test and the clustering were implemented in the GEPAS package
(http://gepas.bioinfo.cnio.es). Red  positive expression; green  nega-
tive expression. Intensity of color is a function of immunohistochemical
expression level. Grade  histological grade assessed by Nottingham
Grading System.
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RESPONSE
We note with interest that data from
Palacios et al. broadly support our orig-
inal observation, and that the data from
van der Groep et al. extend our findings
to include other basal-associated mark-
ers, in this case, epidermal growth factor
receptor (EGFR). It is notable that van
der Groep et al. found that BRCA2-
related breast cancers also tended to
share the basal epithelioid phenotype
previously identified only in BRCA1-
related breast cancers. This result should
be interpreted cautiously, particularly
because only four tumors were studied
and because all four BRCA2 tumors
were estrogen receptor (ER)-negative,
which is unusual. Most BRCA2-related
breast cancers are ER-positive (1).
Moreover, the reports of Sørlie et al. (2)
and Palacios et al. do not suggest that
the basal phenotype of BRCA1-related
breast cancer is likely to be extendible to
BRCA2-related breast cancer.
The data provided by Palacios et al.
suggest that the complete ER/erbB2–
negative, cytokeratin (CK) 5/6-positive
phenotype may not be quite so discrim-
inatory of a BRCA1 mutation if age is
taken into account. However, in light of
our findings and those reported by Pala-
cios et al. and van der Groep et al. we
suggest that basal markers, such as
CK5/6 and its partner CK14, as well as
P-cadherin and EGFR, be evaluated fur-
ther as first-line immunohistochemical
tests for the presence of a germ-line
BRCA1 mutation. The finding of van
der Groep et al. that the BRCA1-related
basal phenotype can be extended to in-
clude the basal-associated marker EGFR
is consistent with the work of Santini et
al. (3), who noted that EGFR expression
was frequently observed only in breast
cancers with a high nuclear grade that
also expressed basal epithelial markers
(3). In a more recent study, long-term
treatment of basal mammary epithelial
cells with EGF resulted in a mobile
rather than a stationary phenotype (4),
possibly indicating a mechanism by
which expression of EGFR influences
the behavior of breast cancer cells that
possess a basal epithelial phenotype.
One question raised by these obser-
vations is whether the basal phenotype
of BRCA1-related breast cancer re-
flects the possible cell of origin of
these tumors (5), or instead, the pres-
ence of CK5/6 merely represents a par-
ticular pattern of differentiation, uncou-
pled from histogenesis (6). Moreover,
whether the CK5/6 intermediate fila-
ments are simply biological bystanders
(7) or contributors in their own right to
the phenotype of BRCA1-related breast
cancer is a key question in determining
the true significance of basal cytokeratin
staining in hereditary breast cancer.
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